SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in BioCardia
Beneficial Ownership Report
Intracoastal Capital, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% passive beneficial ownership stake in BioCardia, Inc. common stock.
Summary
- Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G for BioCardia, Inc.
- The Reporting Persons collectively beneficially own 557,179 shares of BioCardia, Inc. Common Stock.
- This ownership represents approximately 4.99% of the outstanding Common Stock of BioCardia, Inc.
- The beneficial ownership is primarily derived from shares issuable upon exercise of Intracoastal Warrant 1.
- The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
- The percentage of class is calculated based on 5,808,734 shares outstanding as of August 31, 2025, plus 4,800,000 shares issued at the closing of the Securities Purchase Agreement (SPA), and 557,179 shares issuable upon exercise of Intracoastal Warrant 1.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.
Risks
- The warrants (Intracoastal Warrant 1 and Intracoastal Warrant 2) contain blocker provisions, preventing the holder from exercising them to the extent that such exercise would result in beneficial ownership exceeding 4.99% of the Common Stock.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a standard regulatory disclosure of a significant passive ownership stake and does not provide broader industry context or competitive analysis.
Stakeholder Impact
- Shareholders: Disclosure of a significant ownership stake by an institutional investor group can influence market perception and potentially share price.
Key Dates
| Date | Description |
|---|---|
| 08/31/2025 | Date of reported shares of Common Stock outstanding by the Issuer (5,808,734 shares). |
| 09/18/2025 | Date of the event requiring the filing, which is the execution of the Securities Purchase Agreement (SPA) with BioCardia, Inc. |
| 09/19/2025 | Date the Issuer filed a Form 8-K disclosing the Securities Purchase Agreement. |
| 09/24/2025 | Date of the Schedule 13G filing and signatures by the Reporting Persons. |
Keywords
BioCardia, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.